The sellside hacks back Lynparza’s prostate opportunity
The writing had been on the wall for Parp inhibitors in first-line prostate cancer, and last week’s US panel showed no mercy.
Polivy adcom: no overall survival, no problem
A US adcom surprisingly backs Polivy’s front-line use, and blockbuster sales could follow.
Immuno-oncology goes subcutaneous
A pivotal study of Keytruda’s SC formulation is about to read out, but Roche could get to market first.
Ash 2022 preview – Brukinsa has the edge over Calquence
Brukinsa’s head-to-head victory over Imbruvica is confirmed, and the Beigene BTK inhibitor looks better than Calquence too.
